Raed H. Mahmoud and Ibrahim  Khalaf Awath

Tikrit Teaching Hospital, Iraq

Received:  Nov 17, 2022/ Revised: Dec 10, 2022/ Accepted: Dec 15, 2022

Abstract

Asthma is a very common chronic disease involving the respiratory system in which the airways occasionally constrict, become inflamed, and are lined with excessive amounts of mucus, often in response to one or more triggers. The current work represents an experimental study that was conducted in Tikrit Teaching Hospital, during the period from April 2008 to the end of November 2008. Around 90 individuals were included in this study from both genders, their ages were from 18 to 80 years. A total of 70 patients with mild and moderate asthma were included in this study from both genders. Their age range from 18 -80 years. It is evident from this study that the highest percentage was 69.2% in patients with mild asthma on steroids was females and 52.6% in asthmatic patients without steroid therapy males, while in mild asthma without steroids and moderate asthma on steroids the percentage is the same in both genders and which was 37.5% and 50% respectively. There was no significant difference between different study groups regarding gender distribution (P > 0.05).  The mean level of serum malondialdehyde was 3.39 ± 0.42 in mild asthma without steroid therapy, 4.03 ± 0.18 in moderate asthma without steroid therapy, 2.18 ± 0.12 in mild asthma on steroid therapy, while 2.77 ± 0.56 in moderate asthma on steroid therapy and 3.33 ± 0.16 in the control group. reveals that the mean level of serum interleukin-5 was10.78 ± 3.19 in mild asthma without steroid therapy, 16.65 ± 4.99 pg/ml in moderate asthma without steroid therapy, 3.94 ± 0.82 pg/ml in mild asthma on steroid therapy, while 4.10 ± 1.08 pg/ml in moderate asthma on steroid therapy and 3.32 ± 0.38 pg/ml in the control group.

Keywords: Asthma, Mal9ndialdehyde, Interleukin-5, Corticosteroids

References

Angkasekwinai, P., Sodthawon, W., Jeerawattanawart, S., Hansakon, A., Pattanapanyasat, K. and Wang, Y. H. (2017). ILC2s activated by IL-25 promote antigen-specific Th2 and Th9 functions that contribute to the control of Trichinella spiralis infection. PLoS ONE, 12, p. e0184684.

Busse, W. W., Holgate, S., Kerwin, E., Chon, Y., Feng, J. and Lin, J. (2013). Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med., 188, pp. 1294-1302.

Ellwood, P. Asher, M. I., Beasley, R., Clayton, T. O. and Stewart, A. W. (2005). Committee IS. The international study of asthma and allergies in childhood (ISAAC): phase three rationale and methods. Int J Tubercul Lung Dis. 9:10–6.

Network, G. A. (2018). The Global Asthma Report, Auckland, New Zealand.

Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E. and Brusselle, G. (2018). After asthma: redefining airways diseases. Lancet. 391:350–400. doi: 10.1016/S0140-6736(17)30879-6.

Stanojevic, T. S., Moores, G., Gershon, A. S. and Bateman, E. D. and Cruz, A. A. (2012). Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 12:5. doi: 10.1186/1471-2458-12-204.

How to cite this article

Mahmoud, R. H. and  Khalaf Awath, I. (2022). Assessment of serum levels of malondialdehyde and interleukine-5 in asthmatic patients receiving corticosteroid therapy. Chemical and Environmental Science Archives, Vol. 2(4), 35-39. https://doi.org/10.47587/CESA.2022.2401

Licence                  Article Metadata

This work is licensed under a Creative Commons Attribution 4.0 International License.

View Details